NEXT BIOMETRICS GP Surges 14% To End Session On Strong Performance

(VIANEWS) – At 15:56 EST on Thursday, NEXT BIOMETRICS GP’s stock prices surged 14.62% to reach kr5.96 after two consecutive sessions of losses. Meanwhile, the Oslo Bors Benchmark Index_GI is down 0.08% at 1,292.99 following an upward trend from earlier today; thus indicating negative trading today; its previous closing price for NEXT BIOMETRICS GP was 5.20 which is 22.39% below its 52-week high of 6.70.

About NEXT BIOMETRICS GP

NEXT Biometrics Group ASA specializes in the research, development and manufacturing of fingerprint technology products such as sensor modules and readers, subassemblies and face recognition software. Their offerings can be found in point of sale terminals, smart cards, government ID, access control and the internet of things; with distributors of electronic components selling these offerings from Oslo Norway.

Yearly Analysis

According to available data, NEXT BIOMETRICS GP’s stock (KR5.96) is currently trading below its 52-week high price (KR6.70) but higher than its low (KR3.49), suggesting price fluctuations over the last year.

NEXT BIOMETRICS GP’s EBITDA stands at 11.01, representing earnings before factoring in interest, taxes, depreciation and amortization expenses. A positive EBITDA indicates that profits have been generated before considering non-operational expenses such as interest.

Investors should take the current stock price and financial performance of NEXT BIOMETRICS GP into account when making investment decisions. Additional research must also be performed in order to evaluate its potential growth as well as assess risks related to investing in this stock.

Technical Analysis

Recent trading has seen NEXT BIOMETRICS GP (NXBIO.ST) see its stock price climb above both its 50-day moving average of kr5.60 and 200-day moving average of kr5.02. This indicates a short-term uptrend.

Notably, this stock has been relatively volatile recently with an intraday variation average of 0.39% per week over the last seven days, 0.23% per month and 2.22% quarterly – suggesting significant fluctuations in price in the near future.

Stochastic oscillator indicators, which measure overbought and oversold conditions in stocks, currently indicate that NEXT BIOMETRICS GP’s stock may be oversold (=20), suggesting it may be undervalued and poised for price appreciation.

Overall, NEXT BIOMETRICS GP’s current stock price and recent trading activity suggest it may be an attractive buy for investors looking to capitalise on short-term price gains. It is wise to keep an eye on volatility levels as well as devise a long-term investing plan before making this decision.

Quarter Analysis

According to the available data, the company’s year-on-year quarterly revenue growth has decreased by 35.7% compared to its growth last year. With twelve trailing months’ revenue at 41.39M and its year-on-year quarterly growth at just 35.7%, investors may have cause for alarm at its significant revenue decline since last year – yet revenue growth should only be considered when making investment decisions; other aspects such as profitability, competitive positioning and market conditions should also be factored in when making such decisions.

Equity Analysis

According to financial data provided, Next Biometrics GP’s trailing twelve month earnings per share (EPS) stands at kr-0.6, signifying that it has failed to generate any profits over the last year and providing valuable insight for investors as it shows whether or not Next Biometrics can generate earnings for its shareholders. This information is essential when making investment decisions.

Additionally, the return on equity (ROE) for the last twelve trailing months stands at negative 59.74% indicating that no profit has been generated relative to shareholder equity over this period. A negative ROE can serve as a warning sign to potential investors as it suggests that company is misusing shareholder resources effectively in order to generate profits and achieve success.

Given Next Biometrics GP’s poor profitability metrics, investors should proceed with caution when considering investing in it. Prior to making any definitive investment decisions involving Next Biometrics GP it is advisable to conduct more extensive research and analysis on its financials, operations, and industry trends before making their choice.

More news about NEXT BIOMETRICS GP (NEXT.OL).

Leave a Reply

Your email address will not be published. Required fields are marked *